drugset
drugset / Trial / NCT04452461

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

NCT04452461 ↗

Phase 2 Recruiting 30 enrolled Hamilton Health Sciences Corporation
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.

Timeline

Start
2021-03-01
Primary completion
2025-12-12
Completion
2026-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 125 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

pancreatic adenocarcinoma